A new editorial/analysis piece highlights how drug discovery teams are positioning for the “next wave” of proximity degraders—molecular approaches intended to bring targets into degradative proximity to enable degradation of otherwise difficult proteins. The framing centers on platform and discovery approaches rather than a specific clinical asset, reflecting a renewed focus on expanding targetable space in oncology and beyond.